The quest for a vaccine against Helicobacter pylori: How to move from mouse to man?

Microbes and Infection

Volumn 5, Issue 8, 2003, Pages 749-756

  Ruggiero, Paolo ^a   Peppoloni, Samuele ^a   Rappuoli, Rino ^a   Del Giudice, Giuseppe ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Helicobacter pylori; Immune response; Vaccines

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL ANTIGEN; CAGA PROTEIN; CD4 ANTIGEN; CD69 ANTIGEN; CYTOTOXIN; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; HELICOBACTER PYLORI ANTIGEN; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; PLASMID VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREASE;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; B LYMPHOCYTE ACTIVATION; BACTERIAL CELL; CELLULAR IMMUNITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; EXPRESSION VECTOR; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOID CELL; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; REVIEW; SALMONELLA; SALMONELLA ENTERICA; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VACCINATION;

ANIMALIA; HELICOBACTER; HELICOBACTER PYLORI;

EID: 0037565075     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(03)00125-4     Document Type: Review

References (43)

1. Graham D.Y. Therapy of Helicobacter pylori: current status and issues. Gastroenterology. 118:2000;S2-S8.
2. Rupnow M.F., Owens D.K., Shachter R., Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. Helicobacter. 4:1999;272-280.
3. Rupnow M.F., Shachter R., Owens D.K., Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine. 20:2002;879-885.
4. Stratton K.R., Durch J.S., Lawrence R.S. Institute of Medicine, Vaccines for the 21st Century: A Tool for Decision Making. 2001;181-188 National Academy Press, Washington, DC.
5. Rappuoli R., Miller H.I., Falkow S. The intangible value of vaccination. Science. 297:2002;937-938.
6. Sullivan P.B., Thomas J.E., Wight D.G., Neale G., Eastham E.J., Corrah T., Lloyd-Evans N., Greenwood B.M. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch. Dis. Child. 65:1990;189-191.
7. Dale A., Thomas J.E., Darboe M.K., Coward W.A., Harding M., Weaver L.T. Helicobacter pylori infection, gastric acid secretion, and infant growth. J. Pediatr. Gastroenterol. Nutr. 26:1998;393-397.
8. Passaro D.J., Taylor D.N., Meza R., Cabrera L., Gilman R.H., Parsonnet J. Acute Helicobacter pylori infection is followed by an increase in diarrheal disease among Peruvian children. Pediatrics. 108:2001;E87.
9. Shahinian M.L., Passaro D.J., Swerdlow D.L., Mintz E.D., Rodriguez M., Parsonnet J. Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet. 355:2000;377-378.
10. Bhan M.K., Bahl R., Sazawal S., Sinha A., Kumar R., Mahalanabis D., Clements J.D. Association between Helicobacter pylori infection and increased risk of typhoid fever. J. Infect. Dis. 186:2002;1857-1860.
11. Del Giudice G., Covacci A., Telford J.L., Montecucco C., Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol. 19:2001;523-563.
12. Sabarth N., Hurwitz R., Meyer T.F., Bumann D. Multiparameter selection of Helicobacter pylori antigens identifies two novel antigens with high protective efficacy. Infect. Immun. 70:2002;6499-6503.
13. Mobley H.L.T. Urease. Mobley H.L.T., Mendz G.L., Hazell S.L. Helicobacter pyloriPhysiology and Genetics. 2001;179-191 ASM Press, Washington, DC.
14. Covacci A., Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for host cells. J. Exp. M. 191:2000;587-592.
15. Ogura K., Maeda S., Nakao M., Watanabe T., Tada M., Kyutoku T., Yoshida H., Shiratori Y., Omata M. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbils. J. Exp. M. 192:2000;1601-1610.
16. Montecucco C., Rappuoli R. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat. Rev. Mol. Cell Biol. 2:2001;457-466.
17. Marchetti M., Rossi M., Giannelli V., Giuliani M.M., Pizza M., Censini S., Covacci A., Massari P., Pagliaccia C., Manetti R., Telford J.L., Douce G., Dougan G., Rappuoli R., ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 16:1998;33-37.
18. Kleanthous H., Tibbitts T.J., Gray H.L., Myers G.A., Lee C.K., Ermak T.H., Monath T.P. Sterilizing immunity against experimental Helicobacter pylori infection is challenge strain-dependent. Vaccine. 19:2001;4883-4895.
19. Genta R.M., Hamner H.W., Graham D.Y. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum. Pathol. 24:1993;577-583.
20. Quiding-Järbrink M., Lönroth H., Ahlstedt I., Holmgren J., Svennerholm A.M. Human gastric B cell responses can be induced by intestinal immunisation. Gut. 49:2001;512-518.
21. Sutton P., Danon S.J., Walker M., Thompson L.J., Wilson J., Kosaka T., Lee A. Post-immunization gastritis and Helicobacter pylori infection in the mouse: a long term study. Gut. 49:2001;467-473.
22. Garhart C.A., Redline R.W., Nedrud J.G., Czinn S.J. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 70:2002;3529-3538.
23. Kleanthous H., Myers G.A., Georgakopoulos K.M., Tibbitts T.J., Ingrassia J.W., Gray H.L., Ding R., Zhang Z.Z., Lei W., Nichols R., Lee C.K., Ermak T.H., Monath T.P. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 66:1998;2879-2886.
24. Gottwein J.M., Blanchard T.G., Targoni O.S., Eisenberg J.C., Zagorski B.M., Redline R.W., Nedrud J.G., Tary-Lehmann M., Lehmann P.V., Czinn S.J. Protective anti-Helicobacter immunity is induced with aluminium hydroxide or complete Freund's adjuvant by systemic immunization. J. Infect. Dis. 184:2001;308-314.
25. Nedrud J.G. Animal models for Helicobacter immunology and vaccine studies. FEMS Immunol. Med. Microbiol. 24:1999;243-250.
26. Akhiani A.A., Pappo J., Kabok Z., Schoen K., Gao W., Franzén L.E., Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J. Immunol. 169:2002;6977-6984.
27. Garhart C.A., Heinzel F.P., Czinn S.J., Nedrud J.G. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect. Immun. 71:2003;910-921.
28. Czinn S.J., Cai A., Nedrud J.G. Protection of germ-free micr from infection with Helicobacter felis after active oral or passive IgA immunization. Vaccine. 11:1993;637-642.
29. Peppoloni S., Mancianti S., Volpini G., Nuti S., Ruggiero P., Rappuoli R., Blasi E., Del Giudice G. Antibody-dependent macrophage-mediated activity against Helicobacter pylori in the absence of complement. Eur. J. Immunol. 32:2002;2721-2725.
30. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., Mills K.H., Rappuoli R., Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 19:2001;2534-2541.
31. Michetti P., Kreiss C., Kotloff K.L., Porta N., Blanco J.L., Bachmann D., Herranz M., Saldinger P.F., Corthésy-Theulaz I., Losonsky G., Nichols R., Simon J., Stolte M., Ackerman S., Monath T.P., Blum A.L. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 116:1999;804-812.
32. Banerjee S., Medina-Fatimi A., Nichols R., Tendler D., Michetti M., Simon J., Kelly C.P., Monath T.P., Michetti P. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 51:2002;634-640.
33. Sougioultzis S., Lee C.K., Alsahli M., Banerjee S., Cadoz M., Schrader R., Guy B., Bedofrd P., Monath T.P., Kelly C.P., Michetti P. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 21:2002;194-201.
34. DiPetrillo M.D., Tibbetts T., Kleanthous H., Killeen K.P., Hohmann E.L. Safety and immunogenicity of phoP/phoQ-deleted Salonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 18:2000;449-459.
35. Angelakopoulos H., Hohmann E.L. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68:2000;2135-2141.
36. Bumann D., Metzger W.G., Mansouri E., Palme O., Wendland M., Hurwitz R., Haas G., Aebischer T., von Specht B.U., Meyer T.F. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 20:2002;845-852.
37. Moran A.P., Prendergast M.M. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J. Autoimmun. 16:2001;241-256.
38. Kotloff K.L., Sztein M.B., Wasserman S.S., Losonsky G.A., Di Lorenzo S.C., Walker R.I. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69:2001;3581-3590.
39. Losonsky G., Kotloff K.L., Walker R.I. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LTR192 G in H. pylori seronegative individuals. Vaccine. 21:2003;562-565.
40. Tribble D.R., Baqar S., Trespalacios F., Sanders J.W., Walker R., Clements J.D., Scott D.A. Safety and immunogenicity of a 4-dose short interval oral, inactivated whole-cell Campylobacter vaccine co-administered with modified Escherichia coli heat-labile (LTR192G) adjuvant in volunteers. Abstr. S39 Fourth Annual Conference on Vaccine Research:2001.
41. Rossi G., Rossi M., Vitali C.G., Fortuna D., Burroni D., Pancotto L., Capecchi S., Sozzi S., Renzoni G., Braca G., Del Giudice G., Rappuoli R., Ghiara P., Taccini E. A conventional beagle dog model for acute and chronic infection with Helicobacter pylori. Infect. Immun. 67:1999;3112-3120.
42. Malfertheiner P., Schultze V., Del Giudice G., Rosenkranz B., Kaufmann S.H.E., Winau F., Ulrichs T., Theophil E., Jue C.P., Novicki D., Norelli F., Contorni M., Berti D., Lin J.S., Schwenke C., Goldman M., Tornese D., Ganju J., Palla E., Rappuoli R., Scharschmidt B. Phase I safety and immunogenicity of a three-component H. pylori vaccine. Gastroenterology. 122:(Suppl):2002;. A-585, Abstr. W1195.
43. Covacci A., Telford J.L., Del Giudice G., Parsonnet J., Rappuoli R. Helicobacter pylori virulence and genetic geography. Science. 284:1999;1328-1333.